DE60215919D1 - 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel - Google Patents

4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel

Info

Publication number
DE60215919D1
DE60215919D1 DE60215919T DE60215919T DE60215919D1 DE 60215919 D1 DE60215919 D1 DE 60215919D1 DE 60215919 T DE60215919 T DE 60215919T DE 60215919 T DE60215919 T DE 60215919T DE 60215919 D1 DE60215919 D1 DE 60215919D1
Authority
DE
Germany
Prior art keywords
indan
fluoro
benzamide
medicament
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215919T
Other languages
English (en)
Other versions
DE60215919T2 (de
Inventor
Paulus Wohlfart
Teri Suzuki
M Dharanipragada
Alena Safarova
Armin Walser
Hartmut Strobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of DE60215919D1 publication Critical patent/DE60215919D1/de
Publication of DE60215919T2 publication Critical patent/DE60215919T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
DE60215919T 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel Expired - Lifetime DE60215919T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102852 2001-02-13
EP01102852 2001-02-13
PCT/EP2002/001443 WO2002064146A1 (en) 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Publications (2)

Publication Number Publication Date
DE60215919D1 true DE60215919D1 (de) 2006-12-21
DE60215919T2 DE60215919T2 (de) 2007-05-31

Family

ID=8176423

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215919T Expired - Lifetime DE60215919T2 (de) 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel

Country Status (34)

Country Link
US (3) US6617359B2 (de)
EP (1) EP1361882B1 (de)
JP (1) JP4317689B2 (de)
KR (1) KR101017531B1 (de)
CN (1) CN100553631C (de)
AT (1) ATE344669T1 (de)
AU (1) AU2002253009B2 (de)
BG (1) BG66065B1 (de)
BR (1) BR0207178A (de)
CA (1) CA2437966C (de)
CY (1) CY1106278T1 (de)
CZ (1) CZ20032154A3 (de)
DE (1) DE60215919T2 (de)
DK (1) DK1361882T3 (de)
EE (1) EE05302B1 (de)
ES (1) ES2274025T3 (de)
HK (1) HK1062140A1 (de)
HR (1) HRP20030646A2 (de)
HU (1) HUP0302845A3 (de)
IL (2) IL157208A0 (de)
MX (1) MXPA03006841A (de)
MY (1) MY135778A (de)
NO (1) NO333522B1 (de)
NZ (1) NZ527469A (de)
PE (1) PE20020884A1 (de)
PL (1) PL363452A1 (de)
PT (1) PT1361882E (de)
RS (1) RS51645B (de)
RU (1) RU2308946C2 (de)
SI (1) SI1361882T1 (de)
SK (1) SK286513B6 (de)
TW (1) TWI241190B (de)
WO (1) WO2002064146A1 (de)
ZA (1) ZA200305412B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020870A1 (es) * 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388341A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388342A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte, Heteroaryl-kondensierte Cycloalkenylamine und deren Verwendung als Arzneimittel
MEP53108A (en) 2002-10-21 2011-05-10 Janssen Pharmaceutica Nv Substituted tetralins and indanes and their use
EP1581510A4 (de) * 2002-11-22 2006-08-30 Bristol Myers Squibb Co 1-aryl-2-hydroxyethylamideals kaliumkanalöffner
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
US7265246B2 (en) * 2003-07-03 2007-09-04 Eli Lilly And Company Indane derivates as muscarinic receptor agonists
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
EP1529525A1 (de) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS Transkriptionsenhancer zur Zellentherapie-Behandlung von Ischämischer Herzerkrankungen
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
WO2005049000A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Treatment of phenylketonurias with bh4
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
MX2007005039A (es) * 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
US7612080B2 (en) 2004-11-19 2009-11-03 Cincinnati Children's Hospital Medical Center GTPase inhibitors and use thereof for controlling platelet hyperactivity
US20060185492A1 (en) 2005-02-18 2006-08-24 Francois Chianese Shoulder bushing for saw blades
EP1741709A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit gesättigtem Linker, und deren Verwendung als Pharmaka
EP1741708A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
US7795101B2 (en) * 2006-04-03 2010-09-14 United Microelectronics Corp. Method of forming a MOS transistor
EP1905764A1 (de) 2006-09-30 2008-04-02 Sanofi-Aventis Substituierte 2-Phenylbenzimidazole und ihre Verwendung als Pharmazeutika
EP1923062A1 (de) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazole und ihre Verwendung als Pharmazeutika
KR101349187B1 (ko) * 2006-12-05 2014-01-10 (주)아모레퍼시픽 지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1942104A1 (de) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropancarbonsäureamide und deren pharmazeutische Verwendung
EP1939180A1 (de) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamide und ihre Verwendung als Arzneimittel für die Stimulation der Expression der endothelialen NO-Synthase
EP1939181A1 (de) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
EP1964840A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
EP1964841A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine und deren pharmazeutische Verwendung
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
EP2197416A1 (de) * 2007-10-09 2010-06-23 Novartis Ag Pharmazeutische formulierung von valsartan
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
UY33476A (es) 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN105408328B (zh) 2013-03-15 2018-11-16 铁木医药有限公司 sGC刺激剂
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3094327A1 (de) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194386A2 (de) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｓｇｃ刺激剤の固体形態
MA45592A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Promédicaments à base de phosphore de stimulateurs de sgc

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) * 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
AU6497701A (en) * 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
PE20020870A1 (es) 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
HK1062140A1 (en) 2004-10-21
ZA200305412B (en) 2004-09-02
SK286513B6 (sk) 2008-12-05
DE60215919T2 (de) 2007-05-31
CY1106278T1 (el) 2011-10-12
SI1361882T1 (sl) 2007-02-28
EP1361882A1 (de) 2003-11-19
MY135778A (en) 2008-06-30
KR101017531B1 (ko) 2011-02-28
NZ527469A (en) 2005-04-29
WO2002064146A1 (en) 2002-08-22
US6812253B2 (en) 2004-11-02
RU2003127750A (ru) 2005-03-10
HUP0302845A2 (hu) 2003-12-29
NO333522B1 (no) 2013-07-01
PL363452A1 (en) 2004-11-15
PE20020884A1 (es) 2002-11-25
DK1361882T3 (da) 2007-03-12
CN100553631C (zh) 2009-10-28
CZ20032154A3 (cs) 2004-05-12
US20030022939A1 (en) 2003-01-30
PT1361882E (pt) 2007-01-31
KR20030074809A (ko) 2003-09-19
CA2437966C (en) 2011-06-14
EE05302B1 (et) 2010-06-15
CA2437966A1 (en) 2002-08-22
ES2274025T3 (es) 2007-05-16
JP4317689B2 (ja) 2009-08-19
HUP0302845A3 (en) 2005-11-28
ATE344669T1 (de) 2006-11-15
RS61703A (en) 2006-12-15
MXPA03006841A (es) 2003-11-13
RU2308946C2 (ru) 2007-10-27
IL157208A (en) 2009-09-22
TWI241190B (en) 2005-10-11
BG107994A (bg) 2004-08-31
US7202278B2 (en) 2007-04-10
US20040019114A1 (en) 2004-01-29
US6617359B2 (en) 2003-09-09
SK10112003A3 (sk) 2004-01-08
HRP20030646A2 (en) 2005-06-30
US20050054729A1 (en) 2005-03-10
IL157208A0 (en) 2004-02-19
EP1361882B1 (de) 2006-11-08
AU2002253009B2 (en) 2006-09-14
RS51645B (en) 2011-10-31
JP2004518713A (ja) 2004-06-24
BG66065B1 (bg) 2011-01-31
NO20033546L (no) 2003-09-24
EE200300368A (et) 2003-10-15
BR0207178A (pt) 2004-03-30
CN1496264A (zh) 2004-05-12
NO20033546D0 (no) 2003-08-11

Similar Documents

Publication Publication Date Title
DE60215919D1 (de) 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel
DE59911740D1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
NO20065904L (no) Terapeutiske forbindelser
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
SE0200979D0 (sv) New compounds
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0001899D0 (sv) New compounds
NO20060416L (no) Ny anvendelse I
NO20054848L (no) Substituerte p-diaminobenzenderivater
SE0100569D0 (sv) New compounds
MXPA04006051A (es) Bifenilmetil-tiazolidindionas, analogos y su uso como activadores de ppar-gamma.
ATE405261T1 (de) Verwendung von castanospermine derivaten in der behandlung von hepatitis c
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
SE9904674D0 (sv) Novel compounds
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
DE602004023861D1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE60319227D1 (de) Diarylmethylpiperazines als prophylaktische oder therapeutische mittel gegen virale myocarditis
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PT1330246E (pt) Utilizacao de derivados do acido hidroxieicosatetraenoico em cirurgia intraocular
ATE406888T1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition